



Aid for AIDS (AfA) Programme application Confidential

tel 061 285 5423 fax 061 271 674 email info@afa.com.na website www.nhp.com.na Erf 1319, Grove Street Kleine Kuppe, Windhoek PO Box 23064, Windhoek, Namibia Req No: MOHSS 003

The Aid for AIDS (AfA) Programme has its own administration, and is kept strictly confidential in order to reassure members that his/her status will remain confidential at all times.

Please note

Print clearly using **capital** letters, only **one** character per block. Leave **one** block open between words and mark with an **X** where necessary. Attach all supporting documents. To be completed by applicant. Treatment support is a vital part of the AfA Programme. Please fax completed form where possible to fax 061 271 674.

Particulars of patient (must be completed)

Please note Cont	act details must be supplied to enable us to provide you with this support.
Membership number	Benefit option
Title	Initials First name(s)
Surname	
Nationality of passport	ID/Passport number Dependant code
Date of birth	D D M M Y Y Y Y Gender M F Occupation
Tel (H)	Tel (W)
Cell	Fax
Email	
Postal address of choice f	or confidential mail Postal code
What time of day is the l	pest time for AfA to contact you? Morning Afternoon ge?
What is your second lang	nuage?
Contact information	of caregiver if minor is in care of someone else, other than parents (should know your HIV status)
Relationship to patient	
Title	Initials First name(s)
Surname	
Tel (H)	Tel (W)
Cell	



Section 1 Clinical history

Please note Sections 1 to 6 m

Sections 1 to 6 **must** be completed by a registered healthcare provider. **All** questions below must be answered with a **yes or no**. If yes, please provide further detail in the appropriate spaces.

When was the HIV infection fi	rst diagnosed? (please atta	ich reports)					
Type of screening test			Date	D	D M M 2 0 Y	Y	
Is the patient currently being	treated for tuberculosis?				Yes No		
If yes, start date?				\bigcirc D	D M M 2 0 Y	Υ	
Has the patient previously been exposed to antiretrovirals? Yes - MTCT Prophylaxis Yes - Other No							
If yes, please provide details of previous antiretroviral exposure							
Please note ART history - Only for patients being registered on the AfA Programme.							
Drug	g	Date treatment started	Date treatment er	nded	Duration (months)	Reason for disco	ontinuation
Give the current combination	the national is taking						
Please list all other medication	_	udina prophylaxis tra	nditional and h	nerhal r	remedies		
ricuse list all other medication	The patient is taking, men	ading proprigidatis, tre	adicional and n	icibaiii	emedies		
Is the patient allergic to any n	medication?				Yes No		
Sulphonamides	nedication.			$\overline{}$	Yes No		
Other allergies				$\overline{}$	Yes No		
Please specify medication				<u> </u>	, es		
	ation required to pro	vont advorco ci	do offocts	of co	rtain drugs		
	ation required to pre				_		
Is there a history of heavy alcohol intake? (i.e. more than 4 drinks per day for a long period of time) Yes No							
Is there a history of recreation			SD etc.)			Yes	No
Is there a history of any depre						Yes	No
If you have answered yes to a		s, please specify					
	examination						
Please note Weight of	and height must be comple	eted to calculate the	e correct dosag	je.			
Weight (without shoes)	kg	Height (with	out shoes)) cm		
Women only							
Are you pregnant?	Yes No	If pregnant, e	expected date	of del	ivery DDMM	1 2 0 Y Y	
Expected mode of delivery	NVD C/S	Expected da	te for c-section	n	$\begin{bmatrix} D & D & M \end{bmatrix} M$	2 0 Y Y	
Section 4 WHO clinical staging (please indicate disease below stage 3 or 4)							
Stage	1 2	З	4				
Clinical Stage 1	<u>—</u>						
Generalised Lymphadenopathy Yes No						No	
Clinical Stage 2							
Unexplained severe weight loss (>10% of body weight) Yes No.					No		
Unexplained persistent fever > 1 month Yes No						No	
					No		



Pulmonary tuberculosis	Yes No						
Shingles within the last 5-years	Yes No						
Unexplained anaemia, neutropaenia, chronic thrombocytopaenia	Yes No						
Clinical Stage 3							
Unexplained persistent diarrhoea > 1 month	Yes No						
Unexplained persistent fever > 1 month	Yes No						
Persistent oral candidiasis (after first 6 weeks of life)	Yes No						
Severe bacterial infections (e.g Pneumonia)	Yes No						
Oral hairy leukoplakia	Yes No						
Acute necrotizing ulcerative gingivitis/periodontitis	Yes No						
Clinical Stage 4							
HIV wasting syndrome (see clinical guidelines for definitions)							
Is there any degree of peripheral neuropathy?	Yes No						
If yes, please specify Mild	Moderate Severe						
Is there any other significant clinical finding?	Yes No						
If yes, please specify							
Section 5 Special investigation results							
Please note Please provide copies of reports. Please supply as many results as possible, including baseline reantiretroviral therapy will only be considered if the result and date of a recent CD4 count and verecommended in the Aid for AIDS Clinical Guidelines will be considered for reimbursement. Please contact Aid for AIDS on tel 061 285 5423 or at info@afa.com.na for further information. Motiva considered. Please contact AfA Programme for assistance if required.	iral load is supplied. Only medication se refer to these guidelines or						
Date test performed CD4 count (cells/mm) CD4 % (must be provided for children)	Viral load (copies/ml)						
Additional investigations Test done Date test performed	Results						
Blood count(s) (essential prior to approval of zidovudine) Yes No D D M M Y Y							
Baseline ALT (essential prior to approval of nevirapine) Yes No D D M M Y Y							
Serum creatinine/eGFR (essential for patients with renal failure or prior approval of Tenofovir) Yes No D D M M Y Y Y							
or prior approval of reliajouny							
Section 6 Medication Please note Generic equivalents and fixed dose combination tablets will be authorised unless otherwise stated.							
Antiretroviral therapy Strength (e.g. 10mg) Directions (e.g. 1 tds*) Period in use (month	ns) Period required (months)						
Other medication required - associated with the management of HIV							
Other medication required - associated with the management of HIV Diagnosis Strength (e.g. 10mg) Directions (e.g. 1 tds*) Period in use (month)	ns) Period required (months)						
	ns) Period required (months)						
	ns) Period required (months)						
	Period required (months)						



Particulars of doct	or/specialist (who will be providing ong	oing care)
Title	Initials First name(s)	
Surname		
Practice number		
Tel (W)		Fax
Email		
Postal address		Postal code
Examining doctor/	specialist acknowledgment and declar	ation
	edge that the AfA Programme will rely on such paracknowledge that telephonic discussions will be taped acknowledge that the taped	iculars when making any recommendations regarding payment for treatment to the ed for medico-legal purposes. Practice stamp
I understand that all per- will take all reasonable s the provision of these be I/we therefore, authorise any dependant (also nev is correct. I understand that accept	teps to maintain confidentiality. The programme's interestive to the programme of the programme of the programme of the programme of the programme with the programme of the pro	Imme will be used to determine access to specific benefits for people with HIV. AfA nedical staff will review this information in order to make recommendations regarding for your care, irrespective of the benefits so authorised. It all facility in possession of any medical information regarding myself, the applicant of information that it may require. I warrant that the information in this application formation that it may require will contact me. I herewith authorise AfA and its agents action to third parties for the purpose of scientific, epidemiological and/or financial
	Signature of patient	D D M M 2 O Y Y Date

